COMMUNIQUÉS West-GlobeNewswire

Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
16/04/2018
DEVON, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative [...]
Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
16/04/2018
FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI [...]
Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support
16/04/2018
BRISBANE, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and [...]
Nova Leap Health Corp. Completes Purchase of Second Massachusetts Home Care Business and Reaches $9 Million Annualized Recurring Revenue
16/04/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 16, 2018 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV:NLH) ("Nova Leap" or “the Company”), a [...]
Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma
16/04/2018
Pillar Partners to provide funding for up to three Investigator Initiated Clinical Trials EXTON, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA ), a clinical-stage [...]
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
16/04/2018
CAMBRIDGE, Mass. and BEIJING, China, April 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
IRADIMED CORPORATION to Hold 2018 First Quarter Financial Results Conference Call on April 30th
16/04/2018
WINTER SPRINGS, Fla., April 16, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD ) announced today that the Company will release its 2018 first quarter financial results before the market opens on Monday, [...]
Active Biotech's rights issue over subscribed
16/04/2018
2018-04-16 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD [...]
Share buy-back week 15/2018
16/04/2018
Announcement 16 April 2018 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 3/2018 Coloplast has initiated the first part of the share buy-back programme totalling up [...]
PotNetwork Holdings, Inc. Purchases State of the Art Cryptocurrency Mining Facility
16/04/2018
With 115 Dedicated Cryptocurrency Mining Rigs, The Company Will Diversify By Establishing Itself In The Bitcoin Mining Industry FT LAUDERDALE, Fla., April 16, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--PotNetwork [...]
Gala Pharmaceutical to Launch Its First State-Of-The-Art Cannabis Testing Laboratories
16/04/2018
IRVINE, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Gala Pharmaceutical, Inc. (OTCBB: GLPH ), an emerging cannabis cloning and breeding company, today announced that it expects to build its first state-of-the-art testing [...]
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
16/04/2018
RESEARCH TRIANGLE PARK, N.C., April 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing [...]
Transactions under Novozymes’ stock buyback program
16/04/2018
Please read the full announcement in the attached PDF 2018_14_Stock_Buybackprogram_EN Attachment 2018_14_Stock_Buybackprogram_EN
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy
16/04/2018
Taiho Pharma ceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy Lugano, Switzerland, and Tokyo, Japan, [...]
Shire plc : Rule 2.9 Announcement
16/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 16 April 2018 [...]
Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema
16/04/2018
Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema Herantis Pharma Plc Company release 16 Apr 2018 at 9:00 am Herantis Pharma Plc ("Herantis") announced today positive results [...]
Lysogene Reports First Quarter Financial Results and Provides Business Update
16/04/2018
Extended CNS pipeline with a collaboration agreement for the development of an AAV-based gene therapy for Fragile X syndrome, the most common single gene cause of autism, a condition of high unmet medical need. [...]
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
16/04/2018
Heart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE inhibitor enalapril[1] [...]
Telix Pharmaceuticals, INSERM and ARRONAX Enter into Translational Research Partnership
16/04/2018
MELBOURNE, Australia and NANTES, France, April 16, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of [...]

Pages